Mediadores inflamatórios envolvidos na fisiopatologia da enxaqueca: uma revisão integrativa
DOI:
https://doi.org/10.34024/rnc.2024.v32.16518Palavras-chave:
citocinas, enxaqueca, inflamaçãoResumo
Introdução: A enxaqueca é caracterizada como um distúrbio neurológico que atinge cerca de 10% da população adulta globalmente. A população afetada sofre com uma dor pulsátil, que apresenta intensidade variada, e pode estar associada a náuseas, vômitos, foto e/ou fonofobia e sensibilidade a odores. Algumas citocinas têm sido associadas a patogênese da dor de cabeça na enxaqueca. Estudos evidenciam que os níveis plasmáticos de citocinas pró e anti-inflamatórias flutuaram significativamente em pacientes com enxaqueca. Objetivo: Revisar e identificar na literatura os valores basais dos principais mediadores inflamatórios envolvidos na fisiopatologia da enxaqueca em adultos de ambos os sexos. Método: Realizada uma pesquisa bibliográfica, do tipo revisão integrativa da literatura, com busca dos artigos na plataforma de base de dados PubMed. Resultados: Os achados revelaram que os mediadores inflamatórios: IL-6, TNF, CGRP, PCR, IL-1B, TGF-β1 tiveram concentrações aumentadas em pacientes com enxaqueca, a IL-10 e IL-8 apresentam resultados controversos e sugerem a necessidade de novos estudos com uma análise mais aprofundada. Conclusão: O resultado comparativo dos valores basais das citocinas em pacientes com enxaqueca e controle saudáveis sugerem que elas podem estar ligadas a neuroinflamação que ocorre na enxaqueca.
Métricas
Referências
Martelletti P, Schwedt TJ, Vo P, Ritrovato D, Reilly MC, Naclerio M, et al. Healthcare resource use and indirect costs associated with migraine in Italy: results from the My Migraine Voice survey. J Med Econ 2021;24:717-26. https://doi.org/10.1080/13696998.2021.1925557
Todd C, Lagman-Bartolome AM, Lay C. Women and Migraine: the Role of Hormones. Curr Neurol Neurosci Rep 2018;18:1-6. https://doi.org/10.1007/s11910-018-0845-3
Queiroz LP, Silva Junior AA. The prevalence and impact of headache in Brazil. Headache 2015;55:32-8. https://doi.org/10.1111/head.12511
Silberstein SD. Migraine. Lancet 2004;363:381-91. https://doi.org/10.1016/S0140-6736(04)15440-8
Sumelahti M-L, Sumanen M, Sumanen MS, Tuominen S, Vikkula J, Honkala SM, et al. My Migraine Voice survey: disease impact on healthcare resource utilization, personal and working life in Finland. J Headache Pain 2020;21:118. https://doi.org/10.1186/s10194-020-01185-4
Stovner LJ, Nichols E, Steiner TJ, Abd-Allah F, Abdelalim A, Al-Raddadi RM, et al. Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2018;17:954-76. https://doi.org/10.1016/S1474-4422(18)30322-3
Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001;41:646-67. https://doi.org/10.1046/j.1526-4610.2001.041007646.x
Schulte LH, May A. The migraine generator revisited: continuous scanning of the migraine cycle over 30 days and three spontaneous attacks. Brain 2016;139:1987-93. https://doi.org/10.1093/brain/aww097
Hagen K, Linde M, Steiner TJ, Stovner LJ, Zwart J-A. Risk factors for medication-overuse headache: an 11-year follow-up study. The Nord-Trøndelag Health Studies. Pain 2012;153:56-61. https://doi.org/10.1016/j.pain.2011.08.018
Yamanaka G, Suzuki S, Morishita N, Takeshita M, Kanou K, Takamatsu T, et al. Role of neuroinflammation and blood-brain barrier permutability on migraine. Int J Mol Sci 2021;22:8929. https://doi.org/10.3390/ijms22168929
Perini F, D’Andrea G, Galloni E, et al. Plasma cytokine levels in migraineurs and controls. Headache 2005;45:926-31. https://doi.org/10.1111/j.1526-4610.2005.05135.x
Burgos-Vega CC, Quigley LD, Avona A, Price T, Dussor G. Dural stimulation in rats causes brain-derived neurotrophic factor-dependent priming to subthreshold stimuli including a migraine trigger. Pain 2016;157:2722-30. https://doi.org/10.1097/j.pain.0000000000000692
Shimomura T, Araga S, Esumi E, Takahashi K. Decreased serum interleukin-2 level in patients with chronic headache. Headache 1991;31:310-3. https://doi.org/10.1111/j.1526-4610.1991.hed3105310.x
Fidan I, Yüksel S, Ymir T, Irkeç C, Aksakal FN. The importance of cytokines, chemokines and nitric oxide in pathophysiology of migraine. J Neuroimmunol 2006;171:184-8. https://doi.org/10.1016/j.jneuroim.2005.10.005
Koçer A, Memişoğullari R, Domaç FM, Ilhan A, Koçer E, Okuyucu S, et al. IL-6 levels in migraine patients receiving topiramate. Pain Pract 2009;9:375-9. https://doi.org/10.1111/j.1533-2500.2009.00301.x
Güzel I, Taşdemir N, Celik Y. Evaluation of serum transforming growth factor β1 and C-reactive protein levels in migraine patients. Neurol Neurochirur Polska 2013;47:357-62. https://doi.org/10.5114/ninp.2013.36760
Wang F, He Q, Ren Z, Li F, Chen W, Lin X, et al. Association of serum levels of intercellular adhesion molecule-1 and interleukin-6 with migraine. Neurol Sci 2015;36:535-40. https://doi.org/10.1007/s10072-014-2010-3
Duarte H, Teixeira AL, Rocha NP, Domingues RB. Increased interictal serum levels of CXCL8/IL-8 and CCL3/MIP-1α in migraine. Neurol Sci 2015;6:203-8. https://doi.org/10.1007/s10072-014-1931-1
Oliveira AB, Bachi ALL, Ribeiro RT, Mello MT, Tufik S, Peres MFP. Unbalanced plasma TNF-α and IL-12/IL-10 profile in women with migraine is associated with psychological and physiological outcomes. J Neuroimmunol 2017;313:138-44. https://doi.org/10.1016/j.jneuroim.2017.09.008
Han D. Association of Serum Levels of Calcitonin Gene-related Peptide and Cytokines during Migraine Attacks. Ann Indian Acad Neurol 2019;22:277-81. https://doi.org/10.4103/aian.AIAN_371_18
Cowan RP, Gross NB, Sweeney MD, Sagare AP, Montagne A, Arakaki X, et al. Evidence that blood-CSF barrier transport, but not inflammatory biomarkers, change in migraine, while CSF sVCAM1 associates with migraine frequency and CSF fibrinogen. Headache 2021;61:536-45. https://doi.org/10.1111/head.14088
Verri WA Jr, Cunha TM, Parada CA, Poole S, Cunha FQ, Ferreira SH. Hypernociceptive role of cytokines and chemokines: targets for analgesic drug development? Pharmacol Ther 2006;112:116-38. https://doi.org/10.1016/j.pharmthera.2006.04.001
Empl M, Sostak P, Riedel M, Schwarz M, Müller N, Förderreuther S, et al. Decreased sTNF-RI in migraine patients? Cephalalgia inter J Headache 2023;23:55-8. https://doi.org/10.1046/j.1468-2982.2003.00453.x
Musubire AK, Cheema S, Ray JC, Hutton EJ, Matharu M. Cytokines in primary headache disorders: a systematic review and meta-analysis. J Headache Pain 2023;24:36. https://doi.org/10.1186/s10194-023-01572-7
Biscetti L, De Vanna G, Cresta E, Bellotti A, Corbelli I, Letizia Cupini M, et al. Immunological findings in patients with migraine and other primary headaches: a narrative review. Clin Exp Immunol 2022;207:11-26. https://doi.org/10.1093/cei/uxab025
Austin PJ, Moalem-Taylor G. The neuro-immune balance in neuropathic pain: involvement of inflammatory immune cells, immune-like glial cells and cytokines. J Neuroimmunol 2010;229:26-50. https://doi.org/10.1016/j.jneuroim.2010.08.013
Holzmann B. Modulation of immune responses by the neuropeptide CGRP. Amino Acids 2013;45:1-7. https://doi.org/10.1007/s00726-011-1161-2
Downloads
Publicado
Edição
Seção
Licença
Copyright (c) 2024 Larice Nienkotter, Franciane Bobinski
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Como Citar
Aprovado 2024-09-02
Publicado 2024-09-19
